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Confocal microscopyClinical evidence suggests that statins reduce cancer incidence and mortality. However, there is lack of in vitro
data to show the mechanism by which statins can reduce the malignancies of cancer cells. We used a human B
lymphoma Daudi cells as a model and found that lovastatin inhibited, whereas exogenous cholesterol (Cho)
stimulated, proliferation cell cycle progression in control Daudi cells, but not in the cells when transient receptor
potential canonical 6 (TRPC6) channel was knocked down. Lovastatin decreased, whereas Cho increased, the
levels of intracellular reactive oxygen species (ROS) respectively by decreasing or increasing the expression of
p47-phox and gp91-phox (NOX2). Reducing intracellular ROS with either a mimetic superoxide dismutase
(TEMPOL) or an NADPH oxidase inhibitor (apocynin) inhibited cell proliferation, particularly in Cho-treated
cells. The effects of TEMPOL or apocynin were mimicked by inhibition of TRPC6 with SKF-96365. Lovastatin
decreased TRPC6 expression and activity via a Cho-dependentmechanism,whereas Cho increased TRPC6 expres-
sion and activity via an ROS-dependent mechanism. Consistent with the fact that TRPC6 is a Ca2+-permeable
channel, lovastatin decreased, but Cho increased, intracellular Ca2+ also via ROS. These data suggest that lovastat-
in inhibits malignant B cell proliferation by reducing membrane Cho, intracellular ROS, TRPC6 expression and
activity, and intracellular Ca2+.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
3-Hydroxy-3-methylglutaryl coenzyme-A (HMG-coA) reductase in-
hibitors, commonly knownas statins, arewidely used for reducinghyper-
cholesterolemia, a risk factor of cardiovascular diseases. Randomized
controlled trials for preventing cardiovascular disease have surprisingly
indicated that statins can reduce the incidence of colorectal cancer and
melanoma [29]. Large population-based studies have also shown that
statins reduce the incidence of overall cancers [15]. Therefore, it has
been suggested that statins can prevent cancer [11]. Although epidemio-
logical analyses suggest that statin use is not associatedwith 10 common
cancers [10], more recent studies show that statin use can reduce the riskgy, Emory University School of
nited States. Tel.: +1 404 727
gy, the Fourth AfﬁliatedHospital
District, Harbin, 150001, China.
henbzh@vip.sina.comof several types of cancers [3,9,14,30]. Despite the debate, long-term use
of statins, at least, reduces the incidence of selected cancers; such as:mel-
anoma, endometrial cancer, and non-Hodgkin's lymphomas (NHL) [21].
Statin use also decreases the risk ofNHL inHIV-positive persons [7]. In ad-
dition to reducing cancer incidence, statin use also reduces the overall
cancer mortality [28]. Experimental data suggest that the anti-cancer ef-
fects of statins involve severalmechanisms. In amouse lymphomamodel,
both atorvastatin and lovastatin were shown to decrease lymphoma
mortality by inducing apoptosis of the lymphoma cells [1,2]. In murine
tumor models, lovastatin enhanced the antitumoral and apoptotic activ-
ity of doxorubicin [34]; whereas, in murinemelanoma cells, statins stim-
ulate membrane FasL expression and induce lymphocyte apoptosis
through the RhoA/ROCK pathway [37]. Lovastatin also inhibitsmetastasis
of B-cell lymphoma [27] and enhances radiation-induced apoptosis of the
lymphoma cells [35]. Besides inducing apoptosis, statins also inhibit pro-
liferation of thyroid cancer cells and cholangiocarcinoma cells [22,50].
However, it remains unknown whether statins can also inhibit lympho-
ma cell proliferation; and, if so, what is the underlying mechanism.
Recent studies suggest that the transient receptor potential canonical
channel 6 (TRPC6) is overexpressed in cervical and breast cancers [17,44]
and plays an important role in malignant cell proliferation in a variety of
895X. Song et al. / Biochimica et Biophysica Acta 1843 (2014) 894–901cancers [6,13,39]. Interestingly, it has been shown that Cho elevates
TRPC6 activity by promoting the physical interaction between TRPC6
and podocin (a Cho-binding protein) [19] and that intracellular Cho is
elevated in lymphoma cells [31]. Since TRPC6 is a Ca2+-permeable chan-
nel [18], it is very likely that the elevated intracellular Cho promotes lym-
phoma cell proliferation by increasing intracellular Ca2+ via TRPC6.
Although podocinmediates the stimulatory effect of Cho on TRPC6 activ-
ity [19], other pathways may be also involved. As a component of lipid
rafts, Cho maintains NADPH oxidase activity in breast carcinoma cells
[32]. Intracellular oxidative stress occurs in several types of cancer cells
[12] including lymphoma cells [41]. Since TRPC6 is stimulated by ROS
[23,26], it is very likely that Cho stimulates TRPC6 also by elevating intra-
cellular ROS. These studies together suggest that statins may inhibit
lymphoma cell proliferation by reducing TRPC6 channel activity through
its inhibition of Cho synthesis. The present study suggests that lovastatin
inhibits, whereas cholesterol stimulates, human lymphoma B cell prolif-
eration by respectively decreasing or increasing intracellular ROS,
TRPC6 expression/activity, and intracellular Ca2+.
2. Materials and methods
2.1. Cell culture
Human B lymphoma Daudi cells were purchased from American
Type Culture Collection. Daudi cells were suspended and maintained
in a medium containing RPMI 1640, 10% fetal bovine serum, 2 mmol/L
glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin, which
was prepared fresh each week. Every two days, the cell suspension
was centrifuged and resuspended in ﬂasks containing fresh medium.
Cells were cultured continuously in a humidiﬁed incubator at 37 °C in
5% CO2. To knock down TRPC6 expression, Daudi cells were transiently
transfected with TRPC6 silencing short hairpin RNA (shRNA) carried by
a lentiviral vector (Santa Cruz Biotechnology). Before the TRPC6 knock-
down cellswere used, the reductionof TRPC6 expressionwas conﬁrmed
by Western blot experiments. All the experiments in this study were
performed at room temperature.
2.2. Cell proliferation assays
Cell proliferationwas evaluated by performing CellTiter 96®AQueous
One Solution Cell Proliferation Assay (MTS) and by analyzing cell cycle.
MTS assay was carried out according to the manufacturer's instruction.
Brieﬂy, Daudi B cells, either under control conditions or after experi-
mental manipulations (as described in the Results), were transferred
into 96 well plates. 10 μL of CellTiter 96® AQueous One Solution was
added into each well. After the cells were incubated at 37 °C for 3 h,
the absorbance was detected at 490 nm with the Synergy 4 Microplate
Reader (BioTek). All experiments were repeated three times. Cell cycle
analysis was carried out using the ﬂuorescent ubiquitin-based cell
cycle indicator (Fucci®), as described previously [36]. After the cells
were labeled with Fucci, confocal microscopy experiments were per-
formed using either 488 nm or 543 nm laser to excite the indicator.
The emissions at either 519 nm or 603 nm were measured and used
for imaging analysis.
2.3. Confocal microscopy
Confocal microscopy experiments were performed as we previously
reported [47]. Brieﬂy, to detect cholesterol levels in the plasma mem-
brane of Daudi cells, live cells were incubated with 5 μg/mL ﬁlipin
(Sigma, Cat#: F9765) for 30 min. Since ﬁlipin can be easily oxidized,
the stock solution of ﬁlipin was freshly prepared in methanol at
10 mg/mL. The relative cholesterol levels were semi-quantiﬁed accord-
ing to the total ﬂuorescence intensity. For cell cycle analysis, Daudi
cells were transiently transfected with Premo™ FUCCI Cell Cycle Sensor
(Molecular Probes, Cat#: P36238) according to the protocol provided bythemanufacturer. Premo™ FUCCI contains Premo™ geminin-GFP to label
cells in G2/M phases shown in green and Premo™ Cdt-RFP to label G1/S
phases shown in red. To detect the levels of intracellular ROS, the cells
were incubated with 25 μM 2´,7´-dichlorodihydroﬂuorescein diacetate
(Molecular probe) a membrane-permeable, ROS-sensitive, ﬂuorescent
probe, for 15 min. Prior to the confocal microscopy experiments, the
cells were washed twice with a NaCl bath solution and transferred on a
glass slide with a drop of the NaCl bath solution to keep the cells alive.
In each set of experiments, images were taken using the same parameter
settings.2.4. Western blot and biotinylation
Either control or treated Daudi cells were cultured as described
above. Cell surface levels of gp91-phox were evaluated with biotinyl-
ation experiments. Cell lysates (100 μg) were loaded and electropho-
resed on 10% SDS-PAGE gels for 60 to 90 min. Gels were blotted
onto polyvinylidene ﬂuoride (PVDF) membranes for 1 h at 90 V. After
1 hour blocking with 5% BSA-PBST buffer, PVDF membranes were incu-
bated with primary antibodies (1:1000 dilution) of rabbit polyclonal
antibody to TRPC6 (Sigma, Lot # 8831P1), goat polyclonal antibody to
p47-phox (anti-NCF1, Abcam, Cat# ab795), or rabbit polyclonal antibody
to gp91-phox (EMD Millipore, Cat# 07-024) overnight at 4 °C, and then
incubated with horseradish peroxidase (HRP)-conjugated sheep anti-
rabbit IgG secondary antibody (1:5000 dilution, GE healthcare) for 1 h
after 4 vigorous washes. Finally, blots were visualized with chemilumi-
nescence using the ECL Plus Western Blotting Detection System (GE
healthcare).2.5. Patch-clamp techniques
The whole-cell recordings were performed as we described previ-
ously [47]. Brieﬂy, before electrophysiological analysis, the Daudi cell
suspension was centrifuged and resuspended with the NaCl bath solu-
tion (see Chemicals and Solutions). After repeating this procedure
twice, the cell suspension was added into the patch chamber mounted
on the stage of a Nikon inverted microscope. Polished patch pipettes
of borosilicate glass typically with about 5 MΩ were used for patch-
clamp recording. Patch pipettes were ﬁlled with a NaCl pipette solution
(see Chemicals and Solutions). Only patches with high resistance seals
(above 5 GΩ) were used in the experiment to form the whole-cell con-
ﬁguration. Whole-cell currents were recorded using an Axopatch-200B
ampliﬁer and pClamp 10 software (Molecular Devices) and low-pass
ﬁltered at 2 kHz. A voltage-ramp protocol from−100 to 100 mV was
used to quickly get the current–voltage relationship; the protocol was
given at an interval of 1 min. All the experiments were performed at
22–23 °C.2.6. Measurement of [Ca2+]i
Changes in [Ca2+]i were monitored using fura-2, a UV-excitable
Ca2+ indicator, as we reported previously [45]. Daudi cells were incu-
batedwith 5 μM fura-2 acetoxymethyl ester for 30min in the incubator,
and washed twice with the NaCl bath solution. Using a ﬂuorescence
microscope equipped with dual-excitation and single-emission mono-
chromators, the ﬂuorescent intensity of fura-2 was measured at excita-
tion wavelengths of 340 and 380 nmwith 2.5-nm bandwidth and at an
emission wavelength of 510-nm with 4-nm bandwidth. The emission
signals were excited at both 340 and 380 nm and the ratio of these
signals (340/380) was recorded and calibrated with EGTA (2 mM) and
ionomycin (5 μM). Axon Imaging Workbench version 6.0 software
(Axon instruments) was used for acquisition of intensity images and
conversion to ratios.
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Reagents were obtained from the following sources: RPMI 1640,
fetal bovine serum, glutamine, penicillin/streptomycin, and anti-rabbit
IgG from Invitrogen; ionomycin fromCalbiochem. The NaCl bath solution
contained (in mM): 145 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, and 10 HEPES,
adjusted pH to 7.4 with NaOH. The NaCl pipette solution contained
(in mM): 140 NaCl, 5 KCl, 1 MgCl2, 2 ATP-Na2, 10 HEPES and 50 nM
(1 μM) free Ca2+ (after titration with 2 mM EGTA), adjusted to pH 7.2
with NaOH.
2.8. Statistical analysis
Results are shown asmeans± SD. Student's t-test was used for com-
parison between two groups. One-way analysis of variance was applied
for comparison among multiple groups. Two-way analysis of variance
was applied for comparison among multiple groups with two sub-
groups. Differences with a P value of b0.05 were considered statistically
signiﬁcant.
3. Results
3.1. Lovastatin inhibits humanB lymphoma cell proliferation via a Cho- and
TRPC6-dependent mechanism
To determinewhether Cho affects human Burkitt's lymphomaDaudi
B cell proliferation, Daudi cells were treated for 72 hwith 5 μM lovastat-
in, 30 μg/mL Cho, or 5 μM lovastatin plus 30 μg/mL Cho. MTS assaysFig. 1. Lovastatin inhibits, but Cho promotes, human lymphoma Daudi cell proliferation via TRP
indicated, Daudi cells were either under control conditions or transiently transfected with TRPC
plus 30 μg/mL Cho, respectively. (B) Western blot of TRPC6 from control Daudi cells or the cell
experiments showing similar results. (C) Summary plots of normalized Cho levels in the plasm
methyl-β-cyclodextrin (Mβ-CD, a Cho-depleting compound, as a positive control) for 30 min.
in the methods. Data are from four separate experiments, showing similar results. In each exp
for measuring the total ﬂuorescent intensity. In each group, ﬁve such areas were used to get a
Daudi cells stained with ﬁlipin. Since the ﬂuorescence was hardly seen after treatment with M
same microscopic ﬁeld containing Daudi cells with normal morphology.were performed to evaluate cell proliferation (Fig. 1A). The data showed
that treatment of Daudi cells with lovastatin signiﬁcantly reduced cell
proliferation. In contrast, treatment of the cells with exogenous Cho
strongly stimulated cell proliferation. To determine whether lovastatin
inhibits cell proliferation by reducing Cho, the cells were co-treated
with both lovastatin and Cho. The data showed that the co-treatment
did not affect cell proliferation. These effects were abolished when the
expression of TRPC6 was knocked down (Fig. 1A and B), indicating
that TRPC6 mediates the effects of Cho on Daudi cell proliferation.
Although lovastatin is a well-known Cho synthesis inhibitor, it remains
unclear whether lovastatin can reduce Cho levels in Daudi cells, partic-
ularly the Cho levels in the plasmamembrane. Since the levels of Cho in
the plasma membrane can be easily labeled with a ﬂuorescent Cho
probe (ﬁlipin), confocal microscopy experiments were performed
in the cells stained with ﬁlipin. The data showed that lovastatin signiﬁ-
cantly decreased the levels of Cho in the Daudi cell membrane (Fig. 1C
and D). To determine whether these treatments modulate cell cycle,
the cells were incubated with a cell cycle probe, Fucci. As shown in
Fig. 2A and B, lovastatin caused cell cycle arrest at the G1 phase as
shown by cells in red; the percentage of cells in the G1 phase was in-
creased from 56% ± 5% (control level) to 90% ± 6% (after lovastatin)
as shown by green bars (n = 45; p b 0.001). Conversely, Cho caused
cells to be accumulated at S-G2/M phases as shown by cells in green;
the percentage of cells in S-G2/M phases was increased from 44% ±
5% to 93% (control level) ± 5% (after Cho), as shown by green bars
(n= 45; P b 0.001). However, co-treatment of the cells with both lov-
astatin and Cho did not affect cell cycle progression. Daudi cell growth
was also arrested at the G1 phasewhen TRPC6 expression was knockedC6. (A) MTS assay of cell proliferation. In all the experiments through the study, otherwise
6 shRNA and then treated for 72 h with 5 μM lovastatin, 30 μg/mL Cho, or 5 μM lovastatin
s transiently transfected with either TRPC6 shRNA or control shRNA. Data represent three
a membrane either after each treatment as listed in (A) or after treatment with 20 mM
Cho levels were evaluated with a ﬂuorescent Cho-binding molecule, ﬁlipin, as described
eriment, we randomly circled an area with the similar size and the similar density of cells
n average of the ﬂuorescent intensity. (D) Representative confocal microscopy images of
β-CD, a DIC image was inserted into the lower left corner in the last image to show the
Fig. 2. Lovastatin inhibits, but exogenous Cho stimulates, Daudi cell cycle progression. (A) Representative confocalmicroscopy images of cell cycle analysiswith Fucci. Cells in the G1 phase
are shown in red whereas cells in the S or G2/M phase are shown in green. (B) Summary plots of G1 phase (red bars) versus S-G2/M phase (green bars) after each treatment. Cells
were treated for 72 h with 5 μM lovastatin, 30 μg/mL Cho, 5 μM lovastatin plus 30 μg/mL Cho, TRPC6 shRNA, or 0.5 ng/mL transforming growth factor β (TGF-β, as a positive control
because TGF-β is known to induce G1 arrest [20]).
897X. Song et al. / Biochimica et Biophysica Acta 1843 (2014) 894–901down. These data suggest that lovastatin inhibits proliferation by reduc-
ing Cho synthesis and inhibiting cell cycle progression in malignant
Daudi cells.3.2. Lovastatin decreases, whereas cholesterol increases, intracellular ROS
and TRPC6 expression
Since it has been shown that Cho stimulates NADPHoxidase [32] and
that oxidative stress is closely associated with proliferation of cancer
cells [12] including lymphoma cells [41], lovastatin-induced reduction
of membrane Cho may improve oxidative stress in Daudi cells. There-
fore, intracellular ROS were examined with an ROS probe (DCF). The
data showed that lovastatin signiﬁcantly reduced, but Cho increased, in-
tracellular ROS and that co-treatment of the cells with both lovastatin
and Cho did not affect intracellular ROS (Fig. 3A and B). Cho-induced el-
evation of ROS was abolished both by TEMPOL (a mimetic superoxide
dismutase) and by apocynin (an NADPH oxidase inhibitor), indicating
that superoxide is involved. Taken together, these data suggest that lov-
astatin reduces superoxide levels by decreasing Cho. To determine
whether lovastatin reduces ROS in Daudi cells by decreasing the expres-
sion of p47phox, a regulatory subunit of NADPH oxidase, we performed
Western blot experiments to examine p47-phox and gp91-phox protein
levels. In parallel with the effects on ROS, lovastatin signiﬁcantly re-
duced, whereas Cho signiﬁcantly increased, p47-phox and gp91-phox
expression in Daudi cells. In contrast, co-treatment of the cells with
lovastatin and Cho did not affect p47-phox and gp91-phox expression
(Fig. 3C–G). Recent studies suggest that TRPC6 plays an important
role in cancer cell proliferation [6,13,39]. To determine whether Cho
can stimulate TRPC6 expression by elevating superoxide, one of ROS,
we also examined TRPC6 protein levels. The data showed that Cho sig-
niﬁcantly increased, whereas lovastatin signiﬁcantly reduced, TRPC6
expression. In contrast, co-treatment of the cells with lovastatin and
Cho did not affect TRPC6 expression (Fig. 4A and B). In parallel with
the results of Cho-induced cell proliferation, reducing intracellular ROSwith either TEMPOL or apocynin abolished Cho-induced elevation of
TRPC6 protein levels.
3.3. Lovastatin inhibits cell proliferation by reducing intracellular ROS and
inhibiting TRPC6
To determine whether intracellular ROS and TRPC6 mediate the ef-
fects of lovastatin on cell proliferation, Daudi cells were treated with
lovastatin, Cho, or lovastatin plus Cho for 72 h in the absence or pres-
ence of TEMPOL, apocynin, or SKF-96365. MTS assay was performed
to evaluate cell proliferation (Fig. 5A–C). The data showed that both
TEMPOL and apocynin signiﬁcantly reduced cell proliferation, particu-
larly in the cells treated with Cho, but did not further reduce the prolif-
eration in the cells treated with lovastatin. In parallel, SKF-96365
signiﬁcantly reduced cell proliferation, also particularly in the cells
treated with Cho, but did not further reduce the proliferation in the
cells treated with lovastatin. These data suggest that intracellular ROS
and TRPC6 mediate lovastatin-induced reduction of proliferation in
malignant Daudi B cell cells.
3.4. Lovastatin decreases, whereas Cho increases, intracellular Ca2+ respec-
tively by inhibiting or stimulating TRPC6
Previous studies have shown that TRPC6 is directly activated by the
membrane-permeable diacylglycerol analog, 1-oleoyl-2-acetyl-sn-
glycerol (OAG) [18]. To determine whether manipulation of Cho levels
regulates TRPC6 activity, we evaluated TRPC6 activity by whole-cell
patch-clamp recordings of OAG-sensitive currents and found that lova-
statin signiﬁcantly reduced, but Cho signiﬁcantly increased, OAG-
sensitive currents (Fig. 6A). Application of SKF-96365 (a TRPC6 blocker)
reversibly reduced OAG-sensitive currents. The experiments were
performed using the same patch as a control (Fig. 6C). After the basal
currents (trace a) were recorded, OAG was applied to the cell. Then,
the currents at 5 min after OAG addition were recorded, which exhibit-
ed an increase (trace b). In the presence of OAG, SKF-96365was applied
Fig. 3. Lovastatin reduces, but Cho elevates, intracellular ROS via gp91-phox NADPH oxidase. (A) Representative confocal microscopy images of Daudi cells treated as in Fig. 1, with 30 μg/mL
Cho plus 250 μM TEMPOL (a mimetic superoxide dismutase), or with 10 mM apocynin. Intracellular ROS levels were indicated with a ﬂuorescent ROS probe, DCF. (B) Summary plots
of normalized ﬂuorescence intensity of DCF showing relative ROS levels in Daudi cells after each treatment. (C andD) RepresentativeWestern blot of p47-phox and gp91-phox. (E) Normalized
p47-phox protein levels in Daudi cells from three separate experiments. (F and G) Normalized cell surface (F) and total (G) gp91-phox protein levels in Daudi cells from three separate
experiments.
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exhibited a slow down (trace c). After SKF-96365 was washed out,
the currents were recovered (trace d), as shown in Fig. 6B. To conﬁrm
the involvement of TRPC6, the cells were transiently transfected withFig. 4. Lovastatin reduces, whereas Cho elevates expression of TRPC6 via an NADPH oxidase-depe
TRPC6 protein levels from four separate experiments. Daudi cells were treated as in Fig. 1, but alTRPC6 shRNA. In parallel with the effects on Daudi cell proliferation,
knockdown of TRPC6 signiﬁcantly reduced OAG-sensitive currents,
particularly in the cells treated with Cho, but only moderately reduce
OAG-sensitive currents in the cells treated with lovastatin (Fig. 6C).ndent production of superoxide. (A) RepresentativeWestern blot of TRPC6. (B) Normalized
so treated with 30 μg/mL cholesterol either plus 10 μM apocynin or plus 250 μM TEMPOL.
Fig. 5. Lovastatin inhibits, but Cho promotes, Daudi cell proliferation via an ROS- and TRPC channel-dependent mechanism. (A, B, and C) MTS assay of cell proliferation after Daudi cells
were treated as in Fig. 1, but in the absence or presence of 250 μM TEMPOL (A), 10 μM apocynin (B), or 10 μM SKF-96365 (C).
899X. Song et al. / Biochimica et Biophysica Acta 1843 (2014) 894–901Since TRPC6 is a Ca2+-permeable channel, the levels of intracellular
Ca2+ were measured using the Fura-2 method (Fig. 7). Consistent
with the results from patch-clamp experiments, the data showed
that lovastatin signiﬁcantly reduced, but Cho signiﬁcantly increased in-
tracellular Ca2+, and that in the presence of lovastatin, exogenous Cho
not only abolished the lovastatin-induced reduction of intracellular
Ca2+, but even increased intracellular Ca2+. However, the increase in-
duced by Cho in the presence of lovastatin was still signiﬁcantly smaller
than the increase induced by Cho alone. Treatment of the cells for 48 h
with SKF-96365, TEMPOL, or apocynin signiﬁcantly reduced intracellu-
lar Ca2+, particularly in the cells treated with Cho, but did not reduce
intracellular Ca2+ in the cells treated with lovastatin (Fig. 7). These
data suggest that Cho regulates intracellular Ca2+ via a TRPC6- and
ROS-dependent mechanism.Fig. 6. Lovastatin reduces, but Cho elevates, TRPC6whole-cell current in Daudi cells. (A) Summary
whole-cell currents from Daudi cells treated as in Fig. 1. A voltage-ramp protocol for−100 m
basal current (a), the cell was exposed either to 100 μM OAG to activate TRPC6 channels (b) or
of SKF-96365. (C) Summary plots of OAG-sensitive currents from Daudi cells treated as described
OAG-sensitive currents were achieved by subtracting the basal current from the current at 5 min4. Discussion
NHL ranks ﬁfth in cancer incidence and mortality in the United
States during the period from year 2004 to year 2008 [40]. According
to the American Cancer Society, the incidence rates for NHL have nearly
doubled in recent decades. Recent studies suggest that statins can
reduce both incidence and mortality of several cancers, including lym-
phomas [21]. The present study shows that lovastatin inhibits the prolif-
eration of human Burkitt's lymphoma Daudi B cells by reducing the
levels of Cho in the plasmamembrane, intracellular ROS, TRPC6 expres-
sion and activity, and intracellular Ca2+. Since the assembly and activity
of NADPH oxidases are dependent on the cholesterol-rich membrane
microdomains [32,43], we show that lovastatin reduces intracellular
ROS by decreasing the expression of p47-phox and gp91-phox. Sinceplots of whole-cell currents at 100mVunder each condition as indicated. (B) Representative
V to 100 mV at a holding potential of−60 mV was given every minute. After recording
to SKF-96365 to block TRPC6 channels (c). Blockade of TRPC6 was reversed after washout
in Fig. 1, but either under control conditions or transiently transfected with TRPC6 shRNA.
after activated by 100 μM OAG. All the currents were measured at 100 mV.
Fig. 7. Lovastatin reduces, but Cho elevates, intracellular Ca2+ ([Ca2+]i) in Daudi cells via
an ROS- and TRPC channel-dependent mechanism. Daudi cells were treated as in Fig. 1,
but in the absence (open bars) or presence of 10 μM SKF-96365 (black bars), 250 μM
TEMPOL (grey bars), or 10 μM apocynin (dark grey bars).
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that lovastatin reduces intracellular Ca2+, at least in part, by decreasing
TRPC6 activity in a ROS-dependent manner. It has been shown that in-
tracellular Ca2+ provides important regulatory signals during the cell
cycle [5] and that H2O2 stimulates TRPC6 [16]. Therefore, intracellular
oxidative stress due to elevated levels of p47-phox and gp91-phoxmay
account for malignant proliferation via TRPC6-mediated elevation of
intracellular Ca2+. However, it remains largely unknown how Cho reg-
ulates the expression of p47-phox and gp91-phox.
It appears that TRPC6 plays a dual role in regulating cell fate. In
podocytes, TRPC6-dependent increases of intracellular Ca2+ mediate
apoptosis induced by albumin overload [8], sustained activation of atyp-
ical N-methyl-d-aspartate (NMDA) receptors [24], and high glucose
[26]. Gain-of-function mutations of TRPC6 account for focal segmental
glomerulosclerosis [49], which is caused by podocyte apoptosis [4,46].
Since intracellular Ca2+ regulates both cell proliferation and cell death
[38], we argue that TRPC6-mediated increases in intracellular Ca2+
may regulate both cell proliferation and cell death, depending on its
activity. Moderate activation of TRPC6 should result in a moderate ele-
vation of intracellular Ca2+, which should promote cell proliferation.
In contrast, excess activation of TRPC6 should result in a massive in-
crease in intracellular Ca2+, which causes apoptosis. The present study
shows that Cho elevates intracellular Ca2+ only up to 600 nM. It appears
that intracellular Ca2+ at this concentration stimulates Daudi cell prolif-
eration rather than induces apoptosis. However, it remains completely
unknown what prevents cancer cells from intracellular Ca2+ overload
and allows them to escape from apoptosis.
The concentration of lovastatin we used (5 μM) is much higher than
the plasma concentrations in human subjects administrated with com-
mon dose of lovastatin [33]. However, we found that lovastatin at 5 μM
did not induce apoptosis in CCD cells [25]. Consistently, in the present
study, we also noticed that lovastatin at 5 μM did not cause apoptosis
or any other types of cell death in Daudi cells. Recent studies suggest
that simvastatin can be safely used for patients with myeloma and lym-
phoma at a relatively high dose of 15 mg/kg/day [42]. This dose of simva-
statin used for assisting cancer chemotherapy is almost 100 times higher
than that commonly used for treating hypercholesterolemia. Assuming
the average blood volume is 5000mL, this high dosewould result in a cal-
culated plasma concentration of simvastatin at about 7 μM. Therefore, the
pharmacological concentrations of lovastatin we used in the present
in vitro study provide useful information to guide the use of statins in
cancer chemotherapy. Since recent studies indicate that MTS assay may
underestimate the effects of anti-cancer drug on cell proliferation [48],
the effects of lovastatin on Daudi cell proliferation may be more promis-
ing than what we detected by the MTS assay. In conclusion, the present
study provides strong evidence at the molecular level for supporting
the clinical trials focused on the use of statins in cancer therapy.Conﬂict of interest disclosure
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